Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThermoDox plus standardized RFA vs RFA alone in hepatocellular carcinoma (OPTIMA)
CTR20160128Phase 3Terminated
- Sponsor
- Imunon, Inc.
- Start
- Apr 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin in hepatocellular carcinoma (HCC), sponsored by Imunon, Inc.. Started Apr 2016; status: terminated.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20160128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160128.